Triple Analysis: Colorectal Cancer, Apoptosis and Peptides

Triple Analysis: Colorectal Cancer, Apoptosis and Peptides


January 7, 2013
3686 Pages - SKU: BIOS4939986
License type:
Electronic Access - Single User Fulfilled by Publisher      US $5,175.00
Electronic Access - Global Site License Fulfilled By Publisher       US $12,937.50
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.



More Oncology/Hematology reports by BioSeeker Group AB

Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 262 conjugated ...
Biologicals in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Biologicals in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 1421 biological drugs ...
Proteins in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Proteins in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 353 protein drugs ...
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 285 ...
See all reports like this >>